Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

World MS Day: Opportunities remain for products that fulfil significant unmet needs in the MS market, says GlobalData

The multiple sclerosis (MS) therapeutics market is becoming increasingly crowded, but the overall fulfillment of unmet needs is medium. There are no curative therapies for MS, and most existing disease modifying therapies (DMTs) are only partially effective in preventing relapses, with limited impact on the accrual of disability. This means that most patients still experience […]
Read more

Bio/Pharma industry works to solve worldwide shortage of viral vector component used in many COVID-19 vaccines

The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J), says GlobalData, a leading data and analytics company. GlobalData’s report, ‘The Outlook for Viral […]
Read more
,

Strategic reorganization, increased investment in antibody drug conjugates reaffirm Daiichi Sankyo’s long-term oncology goals, says GlobalData

Japanese pharmaceutical company Daiichi Sankyo received a major headway in the global oncology space with the launch of its first antibody drug conjugate (ADC) therapy trastuzumab (Enhertu). In addition to the strong ADC follow-up pipeline, the establishment of a new unified oncology business unit aligning the US and EU markets and increased investment in ADC […]
Read more

Roflumilast set to launch in 2022 across 7MM

Following Arcutis Biotherapeutics’ announcement of new data from its pivotal DERMIS-1 and DERMIS-2 studies of topical phosphodiesterase-4 (PDE4) inhibitor roflumilast for plaque psoriasis (PsO) at the EADV Spring Symposium, leading data and analytics company, GlobalData, notes that this additional data supports rofilumast’s robust safety and efficacy profile. Tiffany Chan, Immunology Analyst at GlobalData comments: “In […]
Read more

Vertex monopoly of the cystic fibrosis space signaled by another label expansion, says GlobalData

Vertex, the current owner of the entire cystic fibrosis transmembrane conductance regulator (CFTR) modulators’ market share, is expected to remain the market leader over the next decade, says GlobalData, a leading data and analytics company. Mandana Emamzadeh, PhD, Healthcare Analyst at GlobalData, comments: “Many pipeline products have emerged in the early stage of development and […]
Read more

Novartis, Cadila Healthcare lead ankylosing spondylitis digital marketing space in India, reveals GlobalData

The ankylosing spondylosis (AS) treatment landscape in India is moderately established with a few disease-modifying anti-rheumatic drugs (DMARDs) available from innovator companies along with biosimilars and generics. Among the innovator and biosimilar companies, Novartis and Cadila Healthcare are the only companies to offer support to AS patients through digital channels, finds GlobalData, a leading data […]
Read more

US and UK healthcare industry professionals are positive UK will remain attractive destination for healthcare research post-Brexit, says GlobalData

While post-Brexit regulatory changes continue to cause significant uncertainty for the UK’s healthcare sector, the UK Government’s initiatives, such as the Medicines and Medical Devices Act, provide much-needed opportunities to shape the environment for innovative healthcare following Brexit, says GlobalData a leading data and analytics company. GlobalData’s latest report, ‘Brexit and the Healthcare Industry – […]
Read more

Diagnosed incident cases of endometrial cancer in the 8MM projected to increase by 10.6% by 2030, says GlobalData

Diagnosed incident cases of endometrial cancer are expected to increase from 120,883 cases in 2020 to 133,690 in 2030 in the eight major markets (8MM*), at an annual growth rate (AGR) of 1.06%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Endometrial Cancer: Epidemiology Forecast to 2030’, notes that the major […]
Read more

Bristol-Myers Squibb is the ideal collaborator to move Agenus’ preclinical AGEN1777 swiftly into the clinic, says GlobalData

Following today’s news (18 May) that Bristol-Myers Squibb (BMS) has exclusively licensed Agenus’ bispecific anti-TIGIT antibody, AGEN1777, for up to $1.36bn; Sakis Paliouras, PhD, Senior Oncology & Hematology Analyst at GlobalData, a leading data, and analytics company, offers his view: “BMS is betting big on the potential of bispecific technology to increase its already high […]
Read more

Brexit to have more negative impact on UK’s healthcare sector than COVID-19 pandemic, say European healthcare professionals in a GlobalData survey

While the UK-EU Trade and Cooperation Agreement (TCA) removed the prospect of a no-deal Brexit, it introduced a wide range of changes to the UK’s healthcare industry, ranging from border checks to additional regulations for businesses based in the UK and EU. These border restrictions may drastically and permanently reshape the way that businesses trade […]
Read more

CKD- HPT, HP, and HK market forecasted to grow at 6.9% CAGR by 2030

With pipeline approvals of varying mechanisms and an influx of newly diagnosed patients, the chronic kidney disease (CKD)-hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) market is expected to grow at a 6.9% Compound Annual Growth Rate (CAGR) from 2020 to 2030 in the seven major markets (7MM*), according to GlobalData, a leading data and analytics […]
Read more

Celiac disease landscape set to evolve significantly with first CD-specific agent entering the market, says GlobalData

Celiac disease (CD) represents an area of high unmet clinical need as there are no products that have been approved specifically for this indication. Historically, patients have needed to maintain a strict gluten-free diet (GFD) in addition to using corticosteroids and immunosuppressants. However, the disease landscape is set to evolve significantly in the coming years. […]
Read more
1 … 62 63 64 65 66 … 108